Skip to content
Triangle logo TriangleGet started
← All settings

DISEASE & TREATMENT SETTING

ERBITUX: advanced Squamous Cell Carcinoma with EGFR stated without a specific alteration

Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.

Exact scope

1 INDICATIONS AND USAGE ERBITUX ® is an epidermal growth factor receptor (EGFR) antagonist indicated for treatment of: Head and Neck Cancer Locally or regionally advanced squamous cell carcinoma of the head and neck in combination with radiation therapy.

Broader topic: Squamous Cell Carcinoma

Source population
Not part of this definition
Disease extent
advanced
Treatment line
Not part of this definition
Stage
Not part of this definition
Resectability
Not part of this definition
Biomarkers, prior therapy and derivation
molecular
  1. gene
    EGFR
    alteration
    stated without a specific alteration
    status
    present
prior therapy
    derivation status
    source-attested
    derivation note
    Scoped from the FDA approved indication for ERBITUX (product label). Only dimensions stated in that wording are part of this definition.
    source wording
    1 INDICATIONS AND USAGE ERBITUX ® is an epidermal growth factor receptor (EGFR) antagonist indicated for treatment of: Head and Neck Cancer Locally or regionally advanced squamous cell carcinoma of the head and neck in combination with radiation therapy.

    Study evidence for this setting

    2 linked studies · Applicability is a draft source assessment, not a determination of your eligibility.

    NCT01256385 · Registry condition search · Scope: unclear

    Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy

    6 outcome links · 2 safety-group records · 0 quality-of-life measures

    →

    NCT03258554 · Registry condition search · Scope: unclear

    Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin

    6 outcome links · 3 safety-group records · 12 quality-of-life measures

    →
    Source relationships and population-mapping limitations
    bindings
      mappings

        Download this complete draft source relationship record →

        Preserved source evidence · Not medical advice